INNsight Newsletter - February edition

Welcome to the February edition of INNsight Newsletter, where we share with you the latest news and insights from?IQVIA Global Market Insights.?

We have a special webinar coming up next month, “MIDAS Early Bird: Uncovering the defining trends of 2023 and what these hold for 2024 ”. Don't miss it as we uncover the latest pharmaceutical market trends, from post-pandemic recovery to emerging therapy areas, recent launches and transformational developments.

This month's thought leadership includes:

• Overview of the Active Pharmaceutical Ingredient Market
• Long-term Market Sustainability for Infused Biosimilar in the U.S.
• Biopharma M&A Outlook for 2024
• WEBINAR: MIDAS Early Bird - Uncovering the Defining Trends of 2023 and what these hold for 2024

Overview of the Active Pharmaceutical Ingredient Market

The molecule market has shown consistent growth, with key players implementing strategies to maintain this momentum. Based on IQVIA’s MIDAS data, the observed statistical growth highlights the ongoing upward trajectory of the global molecule market driven by diverse factors. This reflects a substantial and enduring uptrend, evident in the compound annual growth rates (CAGR) during the periods from 2014 to MAT 2023. Read more

Long-term Market Sustainability for Infused Biosimilars in the U.S.

This report intends to create a base of foundational analytics to better understand the dynamics of biosimilars. The focus of this report is on infused biosimilars that fall under the buy and bill program in Medicare Part B. In particular, the aim is to understand the key issues that can lead to the sub-optimal functioning of the biosimilars market in the U.S. by analyzing various case studies. Read more

Biopharma M&A Outlook for 2024

Biopharma M&A activity has witnessed a decisive rebound in 2023, with aggregate deal value up by 79% vs. 2022 to reach ~$152Bn for the full year, the highest since 2019. Average deal size also continued its upward trend towards levels last seen in 2020.??As 2024 gets underway, the fundamentals in support of dealmaking continue to be strong and despite such a positive sentiment, some uncertainties remain which may result in potential headwinds for M&A momentum. Read more

Webinar: MIDAS Early Bird - Uncovering the Defining Trends of 2023 and what these hold for 2024

Date: Thursday, March 14, 2024 | Time: 14:30 to 15:30 CET

In this webinar we will provide a first view of key pharma metrics and will analyze the factors behind the growth to help you prepare for what lies ahead in 2024:

• Examine recent launches relative to the historic benchmark
• Look at the evolution of physician engagement through pre- to post-pandemic
• Take a deep dive into the Oncology and Immunology therapy areas, including insights from MIDAS Disease
• Assess the latest trends in the generics and biosimilars sectors
• Review the transformational developments in the Diabetes and Obesity markets

Don't miss this chance to refine your strategy with the latest insights into global sales and volume trends.??Register now!

To learn about IQVIA Global Market Insights' solutions and how we can support your business, follow this link .